Find Clinical Trials

Inclusion Criteria: * Gender is not limited, age 18～60 years old; * Comply with the diagnostic criteria for major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) of the United States of America; * Hamilton rating scale for depression (HAMD) 17-item score ≥ 18; * The medication/psychotherapy received by the subject prior to the start of the study remained stable for at least 4 weeks . Exclusion Criteria: * History of serious somatic diseases or diseases that may affect the central nervous system (e.g., tumors, syphilis, etc.); * Neurological disorders or risk of seizures, such as previous craniosynostosis, head trauma, alcoholism, abnormal electroencephalograms, MRI evidence of structural abnormalities in the brain, or family history of epilepsy; * Patients with bipolar disorder and depression due to other psychiatric disorders (e.g., psychoactive and non-dependent substances); * Contraindications to MRI scanning or transcranial magnetic stimulation therapy, such as metal or electronic devices placed in the body (intracranial metal foreign bodies, cochlear implants, pacemakers and stents and other metal foreign bodies), space phobia; * People with psychotic symptoms requiring joint application of antipsychotic drugs; * Those with high risk of suicide, or those who have already committed suicide or serious self-injury behavior requiring urgent intervention; * Those who are pregnant, breastfeeding or planning to become pregnant during the trial; * Other conditions judged by the investigator to be unsuitable as research subjects.

Inclusion Criteria: 1. 35 ≤ Age \< 80 years. 2. Regularly attend the clinic for hypertension treatment during the study period, without plans of traveling during the study period. 3. Diagnosed with hypertension, with SBP ≥140mmHg at screening. 4. Currently taking 0 or 2 classes of antihypertensive medications (A/C/D), with or without concurrent use of class B. 5. Willing to participate in the trial and capable of providing written informed consent. Exclusion Criteria: 1. Physician-diagnosed or suspected secondary hypertension (e.g., hypertension caused by renal disease, renal artery stenosis, aortic stenosis, primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid dysfunction, intracranial disease, drug-induced, or rare monogenic genetic disease). 2. SBP ≥180mmHg and/or DBP ≥110mmHg at the screening visit. 3. Suspected or diagnosed white coat hypertension. 4. History of coronary heart disease. 5. History of heart failure. 6. Intolerance to 2 or more classes of A, C,D antihypertensive medications. 7. Currently taking antihypertensive medications other than class A,B,C and D. 8. Diagnosed chronic kidney disease, estimating Glomerular Filtration Rate (eGFR)\< 60 ml/min·1.73m2, or receiving dialysis. 9. Serious medical conditions (e.g., malignant cancer and hepatic dysfunction) 10. Currently in an acute episode of disease (e.g, new-onset cardiovascular and cerebrovascular disease occurred within 3 months). 11. Cognitive or communicative disorders. 12. Currently pregnant or breastfeeding or planning a pregnant or breastfeeding during the study. 13. Reluctant to take antihypertensive medications or have poor compliance with previous treatment. 14. Participating in other clinical trials.

Inclusion Criteria: * availability of a signed Informed Consent (Information Sheet) of the patient to participate in the clinical trial; * female patients in the postmenopausal period (1-4 years) with hypertension (stage I-II, stage I-II), which is established according to the classification of arterial hypertension (HTN) by stages, degrees and cardiovascular risk. Accordingly, the indicators SBP within 140 - 159 mmHg, DBP 90 - 99 mmHg - HTN stage I; SBP within 160 - 179 mmHg, DBP 100 - 109 mmHg - HTN stage II. Depending on the damage to target organs: Stage I - objective signs of organic damage to target organs are absent; Stage II - there are objective signs of target organ damage without symptoms or dysfunction: LV hypertrophy (according to ECG, Echo-CG, MRI). * reduced bone mineral density (BMD), which meets the criteria for osteopenia of the I-III degree, established by ultrasound densitometry: osteopenia of the I degree T-score from -1.0 to -1.5, II degree T-score from -1.5 to -2.0, III degree T-score from -2.0 to -2.5; * patient's readiness for adequate cooperation in the process of clinical trials. Exclusion Criteria: * diagnosed congenital or acquired heart defects; * established non-coronary myocardial diseases (myocarditis, cardiomyopathy); * rhythm or conduction disorders with concomitant hemodynamic disorders (extrasystoles, paroxysmal tachycardias, atrial fibrillation/flutter, AV block 2 and 3 degrees); * endocrine diseases, blood system diseases, systemic connective tissue diseases; * diagnosed chronic obstructive pulmonary disease; * impaired renal function (glomerular filtration rate according to the CKD-EPI formula less than 60 ml/min), liver. * verified oncological diseases; * abnormal uterine bleeding, endometriosis, pelvic inflammatory diseases; * endometrial polyps and large uterine fibroids; * inflammatory bowel diseases (IBD): Crohn's disease, nonspecific ulcerative colitis; * hormone therapy; * artificial early menopause; * HIV/AIDS; * alcohol or drug addiction; * intolerance or allergic reaction to resveratrol, microcrystalline cellulose, grapes, red wine or blueberries; * participation in other clinical trials

Inclusion Criteria: * subject must be pregnant (singleton pregnancy) * \<30 weeks' gestation, age 18 or above * able to provide written consent in English Exclusion Criteria: * The study team and/or PI may exclude anyone deemed unsafe to participate in the protocol.

Inclusion Criteria * Archival or fresh tumor tissue comprised of TNBC or HR+/HER2-negative invasive breast cancer available for NECTIN4 gene amplification testing. * Confirmed NECTIN4 gene amplification by an analytically validated clinical trial assay (CTA). * Measurable disease as defined by RECIST v1.1. * Life expectancy ≥ 12 weeks. * Eastern Cooperative Oncology Group Performance Status (ECOG PS) of ≤ 1. 1. Cohort A Specific Inclusion Criteria: Histologically or cytologically confirmed HR+/HER2-negative endocrine resistant/refractory breast cancer according to ASCO-CAP guidelines and received at least 1 and up to 3 prior lines of non-endocrine-based therapy for advanced disease. 2. Cohort B Specific Inclusion Criteria: Histologically or cytologically confirmed TNBC, including ER-low positive breast cancers (1-10% of cells expressing hormonal receptors by IHC), according to ASCO-CAP guidelines and have received at least 1 and up to 3 prior lines of systemic therapy for advanced disease. Exclusion Criteria * Prior treatment with any antibody drug conjugate (ADC) containing an Monomethyl Auristatin E (MMAE) (vedotin) payload or other MMAE-based therapy. * Known hypersensitivity or allergy to any of the ingredients of any of the study interventions, or to MMAE. * Previously tested HER2-positive (IHC 3+ or ISH+) on prior pathology testing (per ASCO-CAP guidelines). * Active keratitis or corneal ulcerations. * Active or untreated central nervous system (CNS) metastases. * Uncontrolled diabetes or hypertension. * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). * Active interstitial lung disease or pneumonitis requiring ongoing treatment with steroids (\>10mg/day of prednisone or equivalent) or other immunosuppressive medications. * Requirement, while on study, for treatment with strong inhibitors or strong inducers of human cytochrome P450 3A (CYP3A) or inhibitors of P-glycoprotein (P-gp) including herbal- or food-based inhibitors. * Prior treatment with any systemic anticancer therapy within 28 days or 5 half-lives, whichever is shorter, prior to first dose of study treatment Note: Additional protocol defined Inclusion/Exclusion criteria apply

Inclusion Criteria: * 18 years and older, * Diagnosed with type II diabetes, * Reading and writing, * No physical or psychological communication barriers, * Can read and speak Turkish, * Volunteers Exclusion Criteria: * Diagnosed with type I diabetes

Inclusion Criteria: women aged 40-60 who self-identify as Latina or Hispanic women, are able to read and write in English or Spanish, live in the United States, and can use the app and complete online data collection using a smart phone, tablet, or computer. \- Exclusion Criteria: pregnancy within 3 months of starting the study, having or being of high risk for cardiovascular or musculoskeletal illnesses or injuries \-

Inclusion Criteria: 1. TBI patients arriving at the emergency room in the first 24 hours following trauma. 2. Abnormal computed tomography (CT), with a primary injury including any epidural, intracerebral, or subdural collection with a midline shift \>3mm and any basal cistern compression with at least 2 abnormal findings in the initial evaluation at the emergency room (including optic nerve ultrasound \> 6mm at the same side of the CT´s primary injury or and/or an abnormal pupillometry with a reduced (Maximum Contraction Velocity) MCV in the pupil of the same side of the CT´s primary injury, or/and a Trans- Cranial Doppler (TCD) with Pulsatility Index (PI) \> 1.3 and/or Middle Cerebral Artery - Diastolic Velocity (MCA-DV) \< 20cm/seg on the same side of the CT´s primary injury or/and an Intracranial Pressure Pulse Wave (ICPPW) ICPPW2 \> ICPPW1 waveform pattern in the same side of the CT´s primary injury). 3. Age 18 to 70 years old. 4. Patients with or without polytrauma with survival expectancy \>24 hours. 5. Cranial decompression or cranial expansion surgical procedures less than 24 hours after the trauma. Exclusion Criteria: 1. TBI patients arriving at the emergency room after 24 hours following trauma. 2. Normal CT scan at the emergency room. 3. Abnormal CT scan at the emergency room with any primary injury and midline shift less than 3mm or without basal cistern compression and with normal values in at least two different modalities of assessing ICCS (pupillometry, optic nerve sheath ultrasound, transcranial Doppler and/or non-invasive ICP waveform analyzer). 4. Age less than 18 or more than 70 years old. 5. Polytrauma or massive brain injury with survival expectancy \< 24 hours. 6. Cranial decompression or cranial expansion surgical procedures performed \> 24 hours after the trauma.

Inclusion Criteria: * age of the patient will be ranged from 35 to 55 years; 2) weight range 60-85 kg, height 155-170 cm; 3) total burned surface area (TBSA) was more than 40% measured by the rule of nines; 4) the burn cause was thermal; 5) burn depth, partial-thickness burn injury; 6) at least 3 months after burn injuries; 7) and with low physical activity level. Exclusion Criteria: * Patients will be excluded if they had 1) inhalation injury; 2) leg amputation; 3) any limitation in LL range of motion; 4) auditory or visual problems; 5) congenital musculoskeletal deformities, especially in the foot; 6) psychiatric disorders; 7) paralysis; or 8) cardiac abnormalities or cardiac pacemakers.

Inclusion Criteria: * patients suspected with breast cancer. Exclusion Criteria: * patient with glucose level \>200 mg/dl. * Pregnant patients

Inclusion Criteria: 1. Ischemic stroke confirmed by MRI, or hemorrhagic stroke diagnosed by CT or MRI. 2. Age ≥ 18 years. 3. Pre-stroke modified Rankin Scale (mRS) score of 0, 1, or 2. 4. Post-stroke mRS score of 0, 1, 2, 3, or 4 at enrollment. 5. Able to undergo cognitive function screening and other scale assessments within 30 days post-stroke. Exclusion Criteria: 1. Transient ischemic stroke and subarachnoid hemorrhage. 2. Clear and severe psychiatric or emotional disorders before the stroke, including schizophrenia, major depressive disorder, and bipolar disorder. 3. History of clinical stroke within three months prior to enrollment. 4. Unable to communicate or cooperate for assessments due to severe aphasia. 5. Severe dementia prior to the stroke. 6. Pre-stroke modified Rankin Scale (mRS) score ≥ 3. 7. Post-stroke mRS score of 5 at enrollment. 8. History of cancer with an expected life expectancy of less than one year. 9. Expected life expectancy of less than one year due to other medical conditions. 10. Anticipated inability to complete a one-year follow-up. 11. Other situations deemed unsuitable for enrollment by the clinical investigator.

Inclusion Criteria: Subjects are eligible for inclusion in the study only if all the following criteria apply: 1. Men or women who are 18 years of age or older on the day of signing the informed consent; 2. Patients with advanced breast cancer that is inoperable or has metastasized, confirmed by histology or cytology; 3. Patients who, after MDT discussion at the metastatic breast cancer stage, are considered suitable for radiotherapy and have completed radiotherapy; 4. Patients who have previously received and continue to use immunotherapy, or are planned to receive immunotherapy, and are scheduled to receive a systemic treatment regimen including immunotherapy as chosen by the physician within 3 weeks after completing radiotherapy; 5. Patients with a traceable medical history during treatment; 6. Subjects who are able to sign an informed consent to participate in the study. Exclusion Criteria: 1. Subjects with brain metastases or leptomeningeal metastases; if there are any suspected symptoms or signs of CNS involvement, they should be excluded by a cranial MRI scan; 2. Have not signed the informed consent form; 3. Pregnant or lactating women; 4. Other conditions deemed unsuitable for inclusion in the study by the investigator.

Inclusion Criteria: * 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth) * Haemoglobin A1c (HbA1c) ≥ 48 or 6.5% and/or confirmed type II DM diagnosed within the last 180 days (+20 days flexibility allowance) * Willing to provide up to 30 mL of blood for each study visit * Willing and eligible to undergo MRI scan (or CT scan if MRI is contraindicated) * Understands the study process and is willing to take part in the study and sign the informed consent form Exclusion Criteria: * Prior type I or type II DM diagnosis \> 6 months * A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis * Under investigation for pancreatic cancer / pancreatic cyst * Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months * Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years * Current chronic or acute oral or systemic steroid use within 3 months of initial HbA1c or diabetes diagnosis (estimate rather than accurate) * Blood transfusion within 1 month * Solid organ transplant recipient * Currently pregnant * Needing dialysis

Inclusion Criteria: 1. Agree to participate in this study 2. Elderly persons aged 65 and above living in long-term care facilities 3. Live in long-term care facilities for at least three months 4. No gender restrictions 5. Be aware, able to communicate in Mandarin and Taiwanese, and be able to express opinions 6. The upper limbs can move freely and there is no disease that causes tremors in the hands (such as Parkinson's disease, hepatic encephalopathy, etc.) Exclusion Criteria: 1. Has participated in gardening-related activities within one month of receiving the case 2. Those diagnosed with terminal illness or whose health condition is rapidly deteriorating 3. Those suffering from Parkinson's disease, serious heart disease, dementia, mental illness (e.g. schizophrenia, bipolar disorder, etc.) 4. Mini-Mental State Examination (MMSE) with cognitive impairment (MMSE scores below 16 points for individuals with no formal education, below 21 points for those with elementary education, and below 24 points for those with junior high school education or higher.) 5. Those who are unable to participate in the event due to severe speech, vision or hearing impairment

* INCLUSION CRITERIA: To be eligible to participate in this study, an affected individual must meet one of the following criteria: * Age 2-12 years at time of enrollment with a BP of at least \>95th percentile or 120/80 mm Hg verified via medical record review and a willingness to provide biological samples, undergo physical exam, provide information related to family and medical history, and undergo imaging/body measurements (e.g., renal ultrasound) * Age 13-17 years at time of enrollment with a BP of at least 130/80 mm Hg verified via medical record review and a willingness to provide biological samples, undergo physical exam, provide information related to family and medical history, and undergo imaging/body measurements (e.g., renal ultrasound) * Age 18 years or more at time of enrollment with a medical history of meeting the criteria outlined in affected individual inclusion criteria 1 or 2, depending on age at diagnosis (verified via medical record review) and a willingness to provide biological samples, undergo physical exam, and provide information related to family and medical history To be eligible to participate in this study, an unaffected individual must meet all of the following criteria: * First-degree relative to a proband (first identified affected family member) in the study * Willingness to provide biological samples, undergo physical exam, and provide information related to family and medical history To be eligible to participate in this study, an individual with a candidate variant (regardless of known COEH status) must meet all of the following criteria: * History of clinical and/or research genomic interrogation * Positive genomic interrogation test result for candidate variant identified in earlier stages of study or in prior studies performed by study team * Willingness to provide information related to family and medical history, provide access to relevant medical records, undergo physical exam, and undergo imaging/body measurements (if 2-17 years of age and evidence of COEH exists) EXCLUSION CRITERIA: An affected individual who meets any of the following criteria will be excluded from participation in this study: * BMI \>95th percentile * Evidence that hypertension is secondary to a known condition (e.g., chronic kidney disease, aortopathy, sleep apnea, etc.) * Impaired decision-making capability, with or without a legally-authorized representative An unaffected individual who meets any of the following criteria will be excluded from participation in this study: * Prior or current diagnosis of COEH * Second-degree or greater relationship to proband * Impaired decision-making capability, with or without a legally-authorized representative An individual with a candidate variant (regardless of known COEH status) who meets any of the following criteria will be excluded from participation in this study: * No prior genomic interrogation findings available for the study team to review to confirm positive candidate variant status * Impaired decision-making capability, with or without a legally-authorized representative

Inclusion Criteria: * For the High school students' group: All students aged 13 years and older, enrolled at the selected Mtshabezi and Matopo High Schools in the Gwanda and Matobo Rural Districts during the five-year period of the project are eligible to participate in the study. Ability to understand and respond to questions on the Youth Risk Behavior Scree questionnaire and PHQ-9 scale. Relevant history of HPV vaccine administration. Ability to obtain parental/guardian consent for participation. \- For the women group: All women and young female adults thirteen to forty-five years old and requesting health services for prenatal, post-partum, family planning and other care during the five-year project period are eligible to participate. Must not have received Hep B and HPV vaccine in the past and have no known contraindications to either of these two vaccines. Are able to understand and respond to the PHQ-9 and Edinburgh Postnatal Depression scales. Must have a valid consent for participation in the study. Exclusion Criteria: * males who are not enrolled in these participating High Schools. * children below the age of thirteen who are not enrolled in high schools and are not seeking prenatal, post-partum and family planning services at these selected health facilities during the project period. * Any eligible potential participant without a valid consent. * Any potential participant who is excluded by a doctor or midwife for a known contraindicating medical condition that can lead to potential harm to the participant or staff. Any potential participant who is unable to understand and respond to the questions being asked. Participants with proof of prior vaccination will be excluded from this part of the study.

Inclusion Criteria: Local recurrent or metastatic breast cancer suitable for chemotherapy, confirmed histologically. HER2-negative breast cancer(according to 2018 ASCO/CAP HER2 test guideline). 18-75 years old. ECOG PS 0～2. life expectancy is not less than 12 weeks. at least one measurable lesion according to RECIST 1.1. received at least two cycles of SG. Signed informed Exclusion Criteria: Patients who did not receive sacituzumab govitecan treatment for two or more cycles Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years. Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial History of neurological or psychiatric disorders Researchers believe that patients are not suitable for any other situation in this study.

Inclusion Criteria: * 18 to 60 yrs., inclusive, * Female or Male, * With current MDD episode according to MINI 7.0.2. duration (≥4 weeks and ≤ 2 yrs.), * Current BMI ≥18.5 and ≤ 35.99 kg/mts2 * MADRS score at screening ≥18 * Currently on an FDA- approved antidepressant medication at a stable therapeutic dose for ≥ 8 weeks, * Psychotherapeutic interventions are allowed if dose/frequency stable for ≥4 weeks, * Anxiety disorders allowed if no more than moderate in severity and are not the main diagnosis, * Using an effective contraceptive method (participants with childbearing potential), and 10)Able to complete study related tasks. Exclusion Criteria: * Treatment resistance during current depressive episode (\>2 treatment trials at adequate doses/duration), including medication and neuromodulation treatments. * Current/lifetime diagnosis of bipolar disorder or schizophrenia spectrum disorders. * Significant risk of suicide according to CSSRS or clinical judgment, or suicidal behavior in the past year. * Psychotic symptoms during the current MDD episode or in the past 6 months. * Current (past month) substance use disorder (nicotine, caffeine allowed). * Current unstable neurological conditions including seizure disorders (infantile seizures are not exclusionary), neurodegenerative disorders, or stroke. * Evidence of severe peripheral neuropathy. * History of moderate to severe traumatic brain injury (e.g., skull fracture or loss of consciousness \>10 minutes) or spinal cord injury. * Unstable clinically significant medical conditions (e.g., uncontrolled hypertension as indicated by a systolic \>150 mmHg or diastolic \>95mmHg). * History of cancer allowed if remitted for the past 5 years. * Use of anticonvulsant medications and calcium channel blockers at screening. * Current severe pain conditions or need for chronic use of pain medication including NSAIDs and opiates. * Implanted electronic medical devices. * Neuromodulation interventions in the past month. * Active skin lesions on electrode placement sites. * pregnant or breastfeeding. * Suspected IQ \<80. * Any other relevant clinical reason as judged by the clinician.

Inclusion Criteria: * Moderate to severe open angle glaucoma * Central corneal thickness between 480 and 610 microns Exclusion Criteria: * surgical history of corneal graft * presence of corneal opacities * Failed prior trabeculectomy

Inclusion Criteria: * Age \> 20 years * Diagnosis of terminal cancer, with an expected life expectancy of less than 6 months- * Patients with sufficient cognitive status to respond to the research staff's evaluation questions Exclusion Criteria: * Patients or their families who refuse to participate * Patients who withdraw from the study * Patients who have participated in other research studies within one month before or during the trial * Patients with suicidal tendencies